U.S. markets close in 3 hours 44 minutes

Medtronic plc (MDT)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
124.83+0.68 (+0.55%)
As of 12:16PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Gap Up

Gap Up

Previous Close124.15
Bid124.56 x 800
Ask124.59 x 800
Day's Range123.95 - 125.01
52 Week Range87.68 - 132.30
Avg. Volume4,726,096
Market Cap167.946B
Beta (5Y Monthly)0.80
PE Ratio (TTM)46.93
EPS (TTM)2.66
Earnings DateAug 24, 2021
Forward Dividend & Yield2.52 (2.03%)
Ex-Dividend DateJun 24, 2021
1y Target Est140.12
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-11% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Should I Buy Medtronic plc (MDT)?
    Insider Monkey

    Should I Buy Medtronic plc (MDT)?

    Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

  • Medtronic (MDT) Progresses in SCS With FDA Nod for Vanta

    Medtronic (MDT) Progresses in SCS With FDA Nod for Vanta

    Vanta utilizes Medtronic's (MDT) proprietary AdaptiveStim technology for personalized pain relief.

  • Medtronic Receives FDA Approval for Neurostimulator; Shares Rise 1.4%

    Medtronic Receives FDA Approval for Neurostimulator; Shares Rise 1.4%

    Shares of Medtronic (MDT) gained 1.4% after the company received approval from the U.S. Food and Drug Administration for Vanta, a recharge-free implantable neurostimulator. The neurostimulator offers personalized pain relief, broad MRI compatibility, and almost double the device life in certain settings. It also uses MDT’s AdaptiveStim technology for customized pain relief that adjusts to the patient’s body position using a built-in accelerometer. (See MDT stock analysis on TipRanks) VP and GM o